News

Under the agreement, Bristol-Myers Squibb will use small interfering RNA (siRNA) molecules formulated by Tekmira in stable nucleic acid-lipid particles (SNALP) to silence target genes of interest. Bristol-Myers

The Phase I study is expected to evaluate the localisation, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localised prostate cancer. SL052

CG400549 is a potential antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which

Rousselot said that previous in-vivo and in-vitro studies carried out with Peptan Hydrolysed Collagen and published in the March 2010 issue of ‘Bone’ have demonstrated the positive effect

Opexa said that the newly issued patents are US patent nos 7,695,713 and 7,658,926, the granted claims of which are directed to its proprietary process for manufacturing its

Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS computational platform discovery technology, which will be used by Epitomics to generate highly

Galapagos and Roche have increased the number of antibody targets in the alliance. In addition, the targets can now also be used as starting points for molecules consisting

US-based Cumberland Pharma has granted an exclusive license to Phebra, an Australian based pharmaceutical company, for commercialisation of Acetadote in Australia. Phebra is now preparing for the Australian

Compugen said that in recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, has demonstrated broad expression in human multiple